Cover Image
市場調查報告書

Fondaparinux(合成抗凝血劑)的全球市場分析:各產品 (品牌藥,學名藥),市場區隔預測

Fondaparinux Market Analysis by Product (Branded/Generic), and Segment Forecasts to 2024

出版商 Grand View Research, Inc. 商品編碼 368006
出版日期 內容資訊 英文 91 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Fondaparinux(合成抗凝血劑)的全球市場分析:各產品 (品牌藥,學名藥),市場區隔預測 Fondaparinux Market Analysis by Product (Branded/Generic), and Segment Forecasts to 2024
出版日期: 2016年07月26日 內容資訊: 英文 91 Pages
簡介

本報告提供全球Fondaparinux市場相關調查,彙整產業預測,以及各產品,各地區趨勢,及加入此市場的主要供應商簡介等資料。

第1章 調查方法與範圍

第2章 摘要整理

第3章 簡介

  • 主要調查結果
  • 價值鏈分析

第4章 製造

  • 製造工程
  • 問題與趨勢

第5章 成本結構

  • 材料詳細
  • 製造成本
  • 人事費用
  • 給付

第6章 全球主要供應商

  • 簡介
    • GlaxoSmithKline (GSK) Plc
    • Alchemia Ltd.
    • Apotex, Inc.
    • Dr Reddy's Laboratories Ltd.
    • ScinoPharm Taiwan., Ltd.
    • Lupin Pharmaceuticals, Inc.
    • Abbott Laboratories, Inc.
  • 市場佔有率趨勢

第7章 市場趨勢

  • 市場規模
  • 市場銷售額
  • 競爭環境

第8章 市場概要

  • 市場區隔及範圍
  • 全球生產量:2011∼2016年
  • 各地區生產量:2011∼2016年
  • 各地區生產量:2011∼2016年
    • 北美
    • 歐洲
    • 亞太地區
    • 中國
    • 其他各國

第9章 市場預測

  • 各地區市場規模預測:2016∼2024年
  • 各地區消費預測:2016∼2024年

第10章 市場動態

  • 推動市場的要素
  • 阻礙市場的要素
  • 市場機會

第11章 投資獲利能力

  • 全球經濟焦點
  • 近幾年趨勢
  • 最新預測
  • 中國的預測
  • 中國的投資
  • 新計劃的獲利能力

圖表

目錄

The global fondaparinux market is expected to reach USD 686.3 million by 2024, according to a new report by Grand View Research, Inc. Fondaparinux is majorly used during knee and hip replacement surgeries. Arixtra, manufactured by GSK group of companies is the branded drug of Fondaparinux. The drug witnessed patent expiry in 2002. As the active molecule is highly complex to manufacture, it faced low generic competition until 2011. Generic manufacturer companies, such as Alchemia Ltd. and Apotex, Inc., received the Abbreviated New Drug Application approval in 2011 and instantly started the production of generic drugs.

Fondaparinux is used as an anticoagulant and shows improved survival compared with low-molecular-weight heparin. It is used for the prevention of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and is administered subcutaneously. Moreover, Fondaparinux lowers the risk of ischemic events

The increasing collaboration between the key players for acquiring the Intellectual Property Rights (IPRs) in order to manufacture the molecule through patented technology is expected to drive growth. For instance, in July 2016 Dr. Reddy's Laboratories Ltd. entered into an agreement with Alchemia Ltd. to purchase the IPRs of fondaparinux sodium for USD 17.5 million. In September 2014, Mylan N.V. purchased branded and generic versions of fondaparinux sodium from Aspen Global, Inc. for USD 225 million. The deal gave Mylan N.V. access to one of the two generics indicated for the treatment of PE.

Further key Findings From the Study Suggest:

Generics and authorized generics of Arixtra (fondaparinux sodium) dominated the market in 2015 with share of over 65.0%.

The introduction of generic drugs in the market by Apotex, Inc., Dr. Reddy's, and Mylan N.V. is expected to drive the market growth.

Branded drug Arixtra is however anticipated to witness declining growth rate majorly owing to patent expiration, high cost, and introduction of low-cost alternatives

North America held the largest market share of the global market in 2015. Key factors attributing to the dominance include constantly increasing geriatric population, rising prevalence of thrombosis, and the introduction of low-cost generics of Fondaparinux in the U.S.

In addition, the increasing number of awareness initiatives undertaken by government and nongovernment organizations for DVT and PE is driving the growth of the market in the North American region.

China's huge population base with the rising disposable income coupled with the increased burden of chronic diseases is expected to be one of the major drivers for the Chinese market over the forecast period.

Moreover, the presence of local active pharmaceutical ingredients manufacturers and contract research organizations in China increased the number of foreign investments in the country. As a result, China is estimated to grow at CAGR of 21.2% till 2024.

Major companies identified in the market include Dr. Reddy's Laboratories, Inc., GSK group of companies, Mylan N.V., and Alchemia among others.

The Fondaparinux market is a consolidated market and is marked by the presence of mergers and acquisitions.

Table of Content

Chapter 1: Research Methodology

  • 1.1 Research Methodology
  • 1.2 Geographic Scope & Assumptions
  • 1.3 Years Considered
  • 1.4 List of Data Sources

Chapter 2: Executive Summary

Chapter 3: Introduction

  • 3.1 Key Findings
  • 3.2 Value Chain Analysis
    • 3.2.1 Upstream
    • 3.2.2 Downstream

Chapter 4: Manufacture

  • 4.1 Manufacturing Process
  • 4.2 Issues and Trends

Chapter 5: Cost Structure

  • 5.1 Bill of Material
  • 5.2 Manufacturing Cost
  • 5.3 Labor Cost
  • 5.4 Depreciation Cost

Chapter 6: Worldwide Key Vendors

  • 6.1 Profile
    • 6.1.1 GlaxoSmithKline (GSK) Plc
      • 6.1.1.1 Company Overview
      • 6.1.1.2 Financial Performance
      • 6.1.1.3 Product Benchmarking
      • 6.1.1.4 Strategic Initiatives
    • 6.1.2 Alchemia Ltd.
      • 6.1.2.1 Company Overview
      • 6.1.2.2 Financial Performance
      • 6.1.2.3 Product Benchmarking
      • 6.1.2.4 Strategic Initiatives
    • 6.1.3 Apotex, Inc.
      • 6.1.3.1 Company Overview
      • 6.1.3.2 Financial Performance
      • 6.1.3.3 Product Benchmarking
      • 6.1.3.4 Strategic Initiatives
    • 6.1.4 Dr Reddy's Laboratories Ltd.
      • 6.1.4.1 Company Overview
      • 6.1.4.2 Financial Performance
      • 6.1.4.3 Product Benchmarking
      • 6.1.4.4 Strategic Initiatives
    • 6.1.5 ScinoPharm Taiwan., Ltd.
      • 6.1.5.1 Company Overview
      • 6.1.5.2 Financial Performance
      • 6.1.5.3 Product Benchmarking
      • 6.1.5.4 Strategic Initiatives
    • 6.1.6 Lupin Pharmaceuticals, Inc.
      • 6.1.6.1 Company Overview
      • 6.1.6.2 Financial Performance
      • 6.1.6.3 Product Benchmarking
      • 6.1.6.4 Strategic Initiatives
    • 6.1.7 Abbott Laboratories, Inc.
      • 6.1.7.1 Company Overview
      • 6.1.7.2 Financial Performance
      • 6.1.7.3 Product Benchmarking
      • 6.1.7.4 Strategic Initiatives
  • 6.2 Market Share Trends

Chapter 7: Market Status

  • 7.1 Market Size, 2015
    • 7.1.1 Global Fondaparinux market, 2011 - 2024 (USD million)
  • 7.2 Market Volume, 2015
    • 7.2.1 Global Fondaparinux market, volume, 2011 - 2024 (Thousand Units)
  • 7.3 Competitive Landscape
    • 7.3.1 Heat Map

Chapter 8: Market Overview (Variables, Trends& Scope)

  • 8.1 Market Segmentation & Scope
  • 8.2 Global Production Volume 2011 - 2016
    • 8.2.1 Global Fondaparinux market, volume, 2011 - 2016 (thousand units)
  • 8.3 Production Volume by Region, 2011-2016
    • 8.3.1 North America
    • 8.3.2 Europe
    • 8.3.3 Asia Pacific
    • 8.3.4 China
    • 8.3.5 RoW
  • 8.4 Global Production Value, 2011 - 2016
    • 8.4.1 Global Fondaparinux market, 2011 - 2016 (USD million)
  • 8.5 Production Value by Region, 2011 - 2016
    • 8.5.1 North America
    • 8.5.2 Europe
    • 8.5.3 Asia Pacific
    • 8.5.4 China
    • 8.5.5 RoW

Chapter 9: Market Forecast

  • 9.1 Regional Market Size Forecast, 2016 to 2024
    • 9.1.1 North America
    • 9.1.2 Europe
    • 9.1.3 Asia Pacific
    • 9.1.4 China
    • 9.1.5 RoW
  • 9.2 Regional Consumption Forecast, 2016- 2024
    • 9.2.1 North America
    • 9.2.2 Europe
    • 9.2.3 Asia Pacific
    • 9.2.4 China
    • 9.2.5 RoW

Chapter 10: Market Dynamics

  • 10.1 Market Drivers
    • 10.1.1 Expanding applications of Fondaparinux in various therapeutic areas
    • 10.1.2 Expanding target audience in the Fondaparinux market
    • 10.1.3 Introduction of generics in the market
  • 10.2 Market Constraints
    • 10.2.1 High setup cost
  • 10.3 Market Opportunities

Chapter 11: Investment Feasibility

  • 11.1 Global Economic Highlight 2015
  • 11.2 Recent Developments
  • 11.3 The Updated Forecast
    • 11.3.1 Advanced Economies
    • 11.3.2 Emerging Markets and Developing Economies
  • 11.4 China Outlook
  • 11.5 Investment in China
    • 11.5.1 Outlook on investment
    • 11.5.2 Growth opportunities
    • 11.5.3 Policy trends
    • 11.5.4 Conclusions
  • 11.6 Feasibility of New Project
    • 11.6.1 Basis and presumptions
    • 11.6.2 New project

List of Tables

  • TABLE 1: Death rates and severe bleeding: Fondaparinux versus low molecular weight heparin
Back to Top